News R&D Release Sep 30, 2022 Announcement: Commencement of Phase II Clinical Trials for Janus Kinase Inhibitor "ROH-201" in Japan Mar 28, 2022 Notice of Commencement of Domestic Phase I Clinical Trial for Ophthalmic Therapeutic Agent "ROH-202" Sep 7, 2021 Announcement of Collaborative Research Agreement for Creating a Solution to Predict Systemic Diseases from Eye Health Information Jul 20, 2021 Announcement of Commencement of Domestic Phase III Clinical Trial for Cytomegalovirus Endotheliitis Jun 30, 2021 We evaluated the performance of rapid test kits for coronavirus (SARS-CoV-2) antigens using laboratory samples. See Past R&D Release R&D News RSS Our way of Research and Development Our group would like to inform you of the idea that ROHTO Pharmaceuticals is important in research and development. Research and Development Activities In addition to conventional research and development in the health & beauty business, ROHTO Pharmaceutical is committed to conducting research on a daily basis by taking on challenges in a wide range of fields in order to bring about innovation, including new businesses. Eye care / Skin care / internal medicine, food/ Regenerative Medicine Research Achievements Research achievements since 2016. Published Papers/Themes of conference presentations Published PapersConference Presentation Theme Intellectual Property Activities Our group would like to introduce Rohto Pharmaceutical's philosophy and initiatives regarding intellectual property.